# K141956: Fibergraft BG Morsels

- Pathway: 510(k) (Special)
- Applicant: Prosidyan, Inc.
- Decided: Aug 13, 2014 after 26 days
- Product code: MQV (Filler, Bone Void, Calcium Compound)
- Device class: 2
- Regulation: 21 CFR 888.3045
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
No predicates in its family tree.
33 later devices descend from it; 3 cite it directly.
0 of 34 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- None. The FDA summary names its predicate without a number.
- (no number) Prosidyan’s BG Morsels Bone Graft Substitute: named in the summary without a submission number

## Most influential descendants
- K151154: FIBERGRAFT BG Morsels (2015), 31 descendants of its own
- K143533: Fibergraft BG Putty Bone Graft Substitute (2015), 31 descendants of its own
- K170306: FIBERGRAFT BG Putty Bone Graft Substitute (2017), 30 descendants of its own
- K222276: CONDUIT Cages; FIBERGRAFT BG Putty (2022), 29 descendants of its own
- K223731: NuVasive Modulus-C Interbody System (2023), 11 descendants of its own

## Indications for use
FIBERGRAFT™ BG Morsels Bone Graft Substitute is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. FIBERGRAFT™ BG Morsels is indicated to be gently packed into bony voids or gaps of the skeletal system (i.e., the extremities and pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process. FIBERGRAFT™ BG Morsels is not indicated for use in load-bearing applications; therefore, standard internal or external stabilization techniques must be followed to obtain rigid stabilization.

Source page: https://510kreport.com/device/K141956
Methodology: https://510kreport.com/methodology